In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 123 for your search:
Cancer Type/Condition:  Lung cancer, small cell
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18
Sponsor: Other
Protocol IDs: P080204, IDRCB 2008-A01386-49, NCT00925444
2.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Haema CBF SCLC UK/AS 01, NCT00168896
3.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: GLiang, NCT01498055
4.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000531141, CRUK-LUNGSTAR, EU-20649, ISRCTN56306957, EUDRACT-2005-005821-71, UCL-BRD/05/129, MREC-06-MRE10-28, CTA-20363-0215-001, CTAAC-C1312-A5335, CTAAC-C1312-A12462, NCT00433498
5.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000531709, CHNT-CONVERT, CHNT-CTAAC-CONVERT-C17052/A815, EU-20669, CHNT-CTAAC-CONVERT-C17052/A8152, NCT00433563
6.

Phase: Phase III
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: STAD-1, 2006-003995-36, NCT00526396
7.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-30610, CALGB 30610, RTOG 0538, NCT00632853
8.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ELCWP 01994, NCT00658580
9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT number 2007-006033-14, NCT00717938
10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DOLG7, NCT00812266
11.

Phase: Phase III
Type: Treatment
Status: Active
Age: 19 to 80
Sponsor: Other
Protocol IDs: CSCLC-0810, NCT00826644
12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ZhejiangCH06, NCT01158170
13.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA184-156, 2011-000850-48, NCT01450761
14.

Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCLC, NCT01487499
15.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IPM3002, NCT01555710
16.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: immatureDC- HMO-CTIL, NCT00278018
17.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: PX-171-007, NCT00531284
18.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PSHCI 08-005, NCT00702962
19.

Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0359-08-HMO-CTIL, NCT00722228
20.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Other
Protocol IDs: F080929010, UAB 0818, NCT00856830
21.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C14007, 2008-006981-27, NCT01045421
22.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 100138, 10-C-0138, NCT01143545
23.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BRD 08/9-O, NCT01221675
24.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Immunogen 0007, NCT01237678
25.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2B3-101-CR-001, NCT01386580
1     
New Search